Stay updated with breaking news from Surmodics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Surmodics will be acquired by GTCR for $43.00 per share, totaling $627 million. This 41.1% premium reflects Surmodics' advancements in surface modification for medical devices and IVD technologies.
GTCR LLC entered into a definitive agreement to acquire Surmodics, Inc. for approximately $620 million on May 28, 2024. Under the terms of the agreement, affiliates of GTCR will acquire all...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Surmodics, Inc. to GTCR for $43.00 per share in cash is fair to Surmodics shareholders. Halper Sadeh encourages...
Surmodics (NASDAQ:SRDX – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at Sidoti in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $43.00 price objective on the stock. Sidoti’s price objective points to a potential upside of 2.09% from the company’s current price. Other equities […]